A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS.
Key secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression.
Other secondary objectives were:
To assess the effect of the two doses of teriflunomide in comparison to placebo on:
To evaluate the safety and tolerability of teriflunomide.
The study consists of:
The overall treatment period was followed by a 4-week elimination follow-up period.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Sijsele-Damme, Belgium
Ostrava - Poruba, 70852, Czechia
Sittard-Geleen, 6162 BG, Netherlands
Zaporizhya, 69035, Ukraine